<DOC>
	<DOCNO>NCT02031939</DOCNO>
	<brief_summary>Although neoadjuvant chemoradiotherapy significantly reduce risk local recurrence locally advanced rectal cancer , systemic failure remain predominant issue probably due insufficient control systemic micro-metastasis neoadjuvant treatment . Induction chemotherapy one studied strategy . However , efficacy induction chemotherapy prior neoadjuvant chemotherapy remain controversial . In previous study , induction chemotherapy , gap chemotherapy combine neoadjuvant chemoradiotherapy improve response rate rectal cancer patient , result confirm clinical trial . Whether new kind treatment optimize neoadjuvant therapy locally advanced rectal cancer still big problem clinical practice . This study focus optimize neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Randomized Controlled Study Optimize Neoadjuvant Chemoradiotherapy Locally Advanced Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Pathological confirm rectal cancer Clinical stage T34 T N1 No metastasis Distance tumor 10cm anal verge No previous radiotherapy Age range 18 70 Eastern Cooperative Oncology Group score system 01 Clinical stage T12 N0 Distance metastasis Multiple primary tumor Cachexy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>neoadjuvant chemoradiotherapy</keyword>
	<keyword>optimization</keyword>
</DOC>